Ibrutinib prescription in B-cell lymphoid neoplasms

Bulletin du cancer
Aurore DougéRichard Lemal

Abstract

Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.

References

Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Mar 19, 2013·Expert Opinion on Pharmacotherapy·Osmond J D'Cruz, Fatih M Uckun
May 31, 2013·American Journal of Hematology·Michael Hallek
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 30, 2014·Experimental Hematology & Oncology·Aileen NoveroDelong Liu
Mar 25, 2014·Nature Reviews. Cancer·Rudi W HendriksLaurens P Kil
May 24, 2014·Leukemia·M DreylingO Hermine
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Nov 2, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alex F Herrera, Eric D Jacobsen
Feb 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahM L Wang
Apr 11, 2015·British Journal of Haematology·Shuang Q ZhangYue Lynn Wang
May 24, 2015·Blood·Steven P Treon

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.